| 2840- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | NA, | CCA, | NA |
| 2841- | FIS, | Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 |
| 2842- | FIS, | Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
| 2832- | FIS, | Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies |
| - | Review, | Var, | NA |
| 1113- | FIS, | Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 949- | FIS, | ATAGJ, | Cisplatin, | Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway |
| - | in-vivo, | BC, | Walker256 | - | in-vitro, | BC, | Walker256 |
| 5392- | FIS, | AsP, | Fisetin topical delivery via ascorbyl palmitate/hyaluronan-enhanced limosomes: a novel paradigm for preventing UVB-induced skin photoaging |
| - | in-vivo, | Nor, | NA |
| 2401- | Flav, | In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2 |
| - | in-vitro, | Nor, | NA |
| 2313- | Flav, | Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism |
| - | Review, | Var, | NA |
| 2642- | Flav, | QC, | Api, | KaempF, | MCT | In Vitro–In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil Type |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 4063- | Flav, | VitB12, | VitB6, | Homocysteine and Dementia: An International Consensus Statement |
| - | Review, | AD, | NA |
| 4060- | Flav, | Vitamin Supplementation and Dementia: A Systematic Review |
| - | Review, | AD, | NA |
| 4250- | Flav, | Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy |
| - | Review, | NA, | NA |
| 4107- | FLS, | Ex, | Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer's disease of 3×Tg mice |
| - | in-vivo, | AD, | NA |
| 4108- | FLS, | Improvement of olfactory function in AD mice mediated by immune responses under 40 Hz light flickering |
| - | in-vivo, | AD, | NA |
| 4121- | FLS, | Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients |
| - | Trial, | AD, | NA |
| - | in-vitro, | Oral, | NA |
| 4022- | FulvicA, | Chemo, | Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats |
| - | in-vivo, | OS, | NA |
| 4024- | FulvicA, | ANTI-CARCINOGENIC ACTIVITY OF SHILAJIT REGARDING TO APOPTOSIS ASSAY IN CANCER CELLS: A SYSTEMATIC REVIEW OF IN-VITRO STUDIES |
| - | Review, | Var, | NA |
| 4025- | FulvicA, | Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | Review, | AD, | NA |
| 4026- | FulvicA, | Shilajitin Cancer Treatment: Probable Mode of Action |
| - | Review, | Var, | NA |
| 4027- | FulvicA, | Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 4028- | FulvicA, | Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 4029- | FulvicA, | Chemo, | Shilajit mitigates chemotherapeutic drug-induced testicular toxicity: Study on testicular germ cell dynamics, steroidogenesis modulation, and Nrf-2/Keap-1 signaling |
| - | in-vivo, | Var, | NA |
| 4030- | FulvicA, | Therapeutic Potential of Fulvic Acid in Chronic Inflammatory Diseases and Diabetes |
| - | Review, | NA, | NA |
| 4018- | FulvicA, | Fe, | Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations |
| - | in-vivo, | AD, | NA |
| 4017- | FulvicA, | Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease |
| - | NA, | AD, | NA |
| 4019- | FulvicA, | Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins |
| - | Review, | AD, | NA |
| 4016- | FulvicA, | Shilajit: A Natural Phytocomplex with Potential Procognitive Activity |
| - | Review, | AD, | NA |
| 4020- | FulvicA, | Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 4021- | FulvicA, | Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 1283- | GA, | immuno, | Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy |
| - | vitro+vivo, | CRC, | NA |
| 1300- | GA, | PacT, | carbop, | Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line |
| - | in-vitro, | BC, | MCF-7 |
| 1773- | GA, | Impact of Gallic Acid on Gut Health: Focus on the Gut Microbiome, Immune Response, and Mechanisms of Action |
| - | Review, | Var, | NA |
| 1624- | GA, | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
| - | in-vitro, | Cerv, | NA |
| 987- | GA, | Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug |
| - | in-vitro, | GBM, | AMGM | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 |
| 997- | GA, | The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H292 | - | in-vitro, | Nor, | HUVECs |
| 947- | GA, | Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Melanoma, | A2780S | - | in-vitro, | Nor, | IOSE364 | - | Human, | NA, | NA |
| 1091- | GA, | Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | HTB-35 |
| 1115- | GA, | Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway |
| - | in-vivo, | GC, | GES-1 |
| 1086- | GA, | Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation |
| - | in-vitro, | AML, | K562 |
| 1065- | GA, | Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression |
| - | vitro+vivo, | Pca, | NA |
| 3719- | GABA, | Treatment Options in Alzheimer´s Disease: The GABA Story |
| - | Review, | AD, | NA |
| 3720- | GABA, | Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review |
| - | Review, | AD, | NA |
| 4248- | Gala, | Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement |
| - | Review, | NA, | NA |
| 935- | Gallo, | Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 934- | Gallo, | Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase |
| - | Analysis, | NA, | NA |
| 5207- | Gallo, | Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism |
| 5206- | Gallo, | Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells |
| - | in-vitro, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid